Evaluation of an [18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma

Theranostics

Volumn 2, Issue 10, 2012, Pages 999-1009

  Kiesewetter, Dale O ^a   Guo, Ning ^a,b   Guo, Jinxia ^a,b   Gao, Haokao ^a,c   Zhu, Lei ^a,d   Ma, Ying ^a   Niu, Gang ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d XIAMEN UNIVERSITY   (China)

Author keywords

18F fluoride; Exendin 4; Insulinoma; PET

Indexed keywords

ALUMINUM; EXENDIN 4; FLUORIDE; FLUORINE 18; GLUCAGON LIKE PEPTIDE 1; N ETHYLMALEIMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULINOMA; ISOTOPE LABELING; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY;

EID: 84870477312     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5276     Document Type: Article

References (28)

1. Fowler JS, Wolf AP. Working against time: Rapid radiotracer synthesis and imaging the human brain. Acc Chem Res. 1997; 30: 181-8.
2. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends in Molecular Med-icine. 2008; 14: 161-8.
3. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas. J Histochem Cytochem. 2008; 56: 841-51.
4. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003; 30: 781-93.
5. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 recep-tor-dependent and -independent pathways. Circulation. 2008; 117: 2340-50.
6. Chatziioannou A, Kehagias D, Mourikis D, Antoniou A, Limouris G, Kaponis A, et al. Imaging and localization of pancreatic insulinomas. Clin Imaging. 2001; 25: 275-83.
7. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like pep-tide-1 by human plasma in-vitro yields an N-terminally truncated pep-tide that is a major endogenous metabolite in-vivo. J Clin Endocrinol Metab. 1995; 80: 952-7.
8. Murage EN, Gao G, Bisello A, Ahn JM. Development of potent gluca-gon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem. 2010; 53: 6412-20.
9. Kiesewetter DO, Jacobson O, Lang L, Chen X. Automated radiochemical synthesis of [18F]FBEM: A thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot. 2011; 69: 410-4.
10. Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, et al. PET of insu-linoma using [18F]-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011; 8: 1775-82.
11. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (syn-thetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117: 77-88.
12. Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006; 47: 2025-33.
13. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radio-therapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res. 2007; 13: 3696-705.
14. Wild D, Wicki A, Mansi R, Behe M, Keil B, Bernhardt P, et al. Exen-din-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med. 2010; 51: 1059-67.
15. Kiesewetter DO, Gao H, Ma Y, Niu G, Quan Q, Guo N, et al. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insu-linoma. Eur J Nucl Med Mol Imaging. 2012; 39: 463-73.
16. Gao H, Kiesewetter DO, Zhang X, Huang X, Guo N, Lang L, et al. PET imaging of glucagon-like peptide receptor upregulation after myocardial ischemia/reperfusion injury. J Nucl Med. 2012; in press.
17. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009; 50: 991-8.
18. Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012; 39: 11-30.
19. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res. 2009; 42: 832-41.
20. Breeman WAP, de Blois E, Chan HS, Konijnenberg M, Kwekkeboom DJ, Krenning EP. Ga-68-labeled DOTA-Peptides and Ga-68-labeled radio-pharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011; 41: 314-21.
21. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009; 36: 729-39.
22. McBride WJ, D'Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, et al. Improved 18F labeling of peptides with a fluo-ride-aluminum-chelate complex. Bioconjug Chem. 2010; 21: 1331-40.
23. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging. 2010; 37: 1345-55.
24. Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, et al. PET of insu-linoma using 18F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011; 8: 1775-82.
25. Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, et al. Re-ducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med. 2008; 49: 1506-11.
26. Fani M, Andre JP, Maecke HR. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Me-dia Mol Imaging. 2008; 3: 67-77.
27. Liu Z, Yan Y, Liu S, Wang F, Chen X. F-18, Cu-64, and Ga-68 Labeled RGD-Bombesin Heterodimeric Peptides for PET Imaging of Breast Can-cer. Bioconjug Chem. 2009; 20: 1016-25.
28. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using Cu-64 bombesin analogs: Side-by-side com-parison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007; 48: 1327-37.